No Detail Found!

NS5A Resistance Associated Mutations to Daclatasvir in Hepatitis C Virus Genotype 3a Treatment Naive and SOF/DCV Treatment Failure Patients

Author(s)
Saima Younas Centre for Applied Molecular Biology, University of the Punjab, 87 West Canal Bank Road Thokar Niaz Baig, Lahore, Pakistan.
Aleena Sumrin Centre for Applied Molecular Biology, University of the Punjab, 87 West Canal Bank Road Thokar Niaz Baig, Lahore, Pakistan.
Abstract
Pakistan has the second highest hepatitis C virus (HCV) prevalence with seroprevalence of 4.5-8.2%, with genotype 3a being most frequently circulating HCV genotype. Current treatment strategies for HCV are based on direct acting antivirals (DAAs), despite high eficacy of antivirals, still therapy failure has been reported in 5-10% cases due to resistance mutations of amino acids. This study was aimed to analyze clinically important resistance associated mutations (RAMs) to daclatasvir (DCV) in HCV GT3a NS5A region in treatment naive and DAA treatment experienced patients, to understand their role in treatment failure. Patients samples and data was collected on prescribed questionnaire. Viral nucleic acid was isolated and amplified by gene specific primers followed by sequencing of NS5A region by Sanger method. Amino acid substitutions were identified by using Geno2Pheno tool. Hepatitis c virus genotype 3a was most prevalent genotype in the study group. Successfully sequenced patients were divided into two group based on their treatment history, as treatment naive and experienced groups. Both groups were analyzed for detection of amino acid mutations at positions 28, 30, 31, 58 and 93. A30T was detected in 7.6%, Y93H in 15.6% P58T as 7.6% while S98G was found in 23% treated patients. However, these mutations were not detected in any of treatment naive patients. Some mutations were identified in both treatment naive and experienced groups i.e., A21T, T64A, H85Y, S103P, D172E, H180N, T183A/V, and E137G. Mutations at position 62 was most commonly detected found at the frequency of 83.8% and 84.6% in treatment naive and experienced patients respectively. While mutations at position M28 and L31 were not identiefid in both groups of current study. Mutations present in both treatment naive as well as in treatment experienced groups suggesting they have no role in DCV resistance, while identification of A30T, Y93H, P58T and S98G in treated patients suggests that DCV RAMs are circulating in Pakistani HCV GT-3a DAAs treated patients, leading to resistance development and treatment failure. Identification of these mutations is important especially in treatment failure patients to design re-treatment strategies.
Publication Details
Page(s) 2601-2611
Published Journal: Pakistan Journal of Zoology, Volume: 56, Issue: 6, Year: 2024

Request the full text from PASTIC

Keywords
Direct Acting Antivirals (DAAs), NS5A, HCV, GT-3a, Resistance associated mutations (RAMs), Daclatasvir (DCV)
References
Abbas Z.,Abbas M. .2020 .The cost of eliminating hepatitis C in Pakistan. , 8(20) : 30036-324.
Afzal M.S.,Shah Z.H.,Ahmed Z.H.,Infect J. .2015 .Recent HCV genotype changing pattern in the Khyber Pakhtunkhwa province of Pakistan; is it pointing out a forthcoming problem? Braz. , 12 : 312-313.
Brunner N.,Bruggmann P. .2021 .Trends of the global hepatitis C disease Burden: Strategies to achieve elimination. J. Prev. Med, 54 : 251-258.
Butt S.,Idrees M.,Akbar H.,Rehman I.,Awan Z.,Afzal S.,Hussain A.,Shahid M.,Manzoor S.,Rafique S. .2010 .The changing epidemiology pattern and frequency distribution of hepatitis C virus in Pakistan. Infect. Genet, 04 : 595-600.
Campos G.R.F.,Ward J.,Chen S.,Bittar C.,Rodrigues J.P.V.,Martinelli A.D.C.,Souza F.F.,Pereira L.R.L.,Rahal P.,Harris M.,Gen M. .2021 .A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir. , 102 : 001582.
Costa V.D.,Pellegrini P.,Rotman V.,Pittella A.M.,Nunes E.P.,Lago B.V.,Lampe E.,Mello F.C.A. .2019 .Resistance mutationsA30K and Y93N associated with treatment failure with sofosbuvir and daclatasvir for hepatitis C virus infection nonresponder patients: Case reports. Viruses, 11 : 1004.
De-Torres-Santos A.P.,Martins-Silva V.C.,MendesCorrea M.C.,Lemos M.F.,de-Mello-Malta F.,Santana R.A.F.,Dastoli R.A.F.,de-Castro V.F.D.,Pinho J.R.R.,Moreira R.C. .2021 .Prevalence and pattern of resistance in NS5A/NS5B in hepatitis C chronic patients genotype 3 examined at a public health laboratory in the state of São Paulo, Brazil. , 14 : 723-730.
Foster G.R.,Afdhal N.,Roberts S.K.,Brau N.,Gane E.J.,Pianko S.,Lawitz E.,Thompson A.,Shifman M.L.,Cooper C.,Towner W.J.,Conway B.,Ruane P.,Bourliere M.,Asselah T.,Berg T.,Zeuzem S.,Rosenberg W.,Agarwal K.,Stedman C.A.,Mo H.,Dvory-Sobol L.,Wang J.,McNally J.,Osinusi A.,Brainard D.M.,McHutchison J.G.,Mazzotta F.,Tran F.,Gordon S.C.,Patel K.,Reau N.,Mangia A.,Sulkowski M.,Investigators M.,Investigators M. .2015 .Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N. Eng. J. Med, 373 : 2608-2617.
Haqqi A.,Munir R.,Khalid M.,Khurram M.,Zaid M.,Ali M.,Shah Z.H.,Ahmed H.,Afzal M.S. .2019 .Prevalence of hepatitis C virus genotypes in Pakistan: Current scenario and review of literature. Viral Immunol, 32 : 402-413.
Hassanin A.,Kamel S.,Waked I.,Fort M.,GHSP-D- M. .2021 .Egypt's ambitious strategy to eliminate hepatitis C virus: A case study. Glob. Hlth. Sci. Pract, 9 : 187-200.
Hayes C.N.,Imamura M.,Chayama K. .2019 .Management of HCV patients in cases of directacting antiviral failure. Expert Rev. Gastroenterol. Hepatol., 13 : 839-848.
Hernandez D.,Zhou N.,Ueland J.,Monikowski A.,McPhee F. .2012 .Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their efects on the antiviral activity of NS5A inhibitors. J. clin. Virol, 12 : 13-18.
Hezode C.,Chevaliez S.,Scoazec G.,Soulier A.,Varaut A.,Bouvier-Alias M.,Ruiz I.,Roudot-Thoraval F.,Mallat A.,Féray C.,Pawlotsky J.M. .2016 .Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology, 63 : 1809-1816.
Hikita H.,Takehara T. .2020 .NS5A-P32 deletion in hepatitis C genotype 1b infection is the most refractory treatment-mediated amino acid change exhibiting resistance to all NS5A inhibitors. Semin. Liver Dis, 40 : 143-153.
Kan T.,Hashimoto S.,Kawabe N.,Murao M.,Nakano T.,Shimazaki H.,Nakaoka K.,Ohki M.,Takagawa Y.,Kurashita T.,Takamura T.,Yoshioka K. .2016 .The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay. J. Gastroenterol., 51 : 63-70.
Khan M.U.,Sadia H.,Irshad A.,Baig A.A.,Ashiq S.,Zahid B.,Sheikh R.,Roshan S.,Ali A.,Shamas S.,Bhinder M.A. .2020 .Detection, quantification and genotype distribution of HCV patients in Lahore, Pakistan by real-time PCR. , 20 : 16-1152.
Kumar A.,Rajput M.K.,Paliwal D.,Yadav A.,Chhabra R.,Singh S. .1850 .Genotyping and diagnostic methods for hepatitis C virus: A need of low-resource countries. Ind. J. med. Res., 147 : 16-455.
Lahser F.,Galloway A.,Hwang P.,Palcza J.,Brunhofer J.,Wah J.L.,Robertson M.,Barr E.,Black T.,Asante-Appiah E.,Haber B. .2018 .Interim analysis of a 3-years follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevircontaining regimens in participants with chronic HCV infection. , 23 : 593-603.
Makuza J.D.,Jeong D.,Soe P.,Bartlett S.,Héctor A.,García V.,Binka M.,Adu P.,Dushimiyimana D.,Dushimiyimana D.,Maliza C.,Nisingizwe M.P.,Rwibasira G.,Tuyishime A.,Janjua N.Z. .2022 .Impact of COVID-19 pandemic on HCV care cascade in Rwanda: Ecological study from July 2019 to June 2021. , 20 : 25-30.
Malta F.M.,Medeiros-Filho J.E.,Azevedo R.S.,Goncalves L.,Da Silva,Carrilho L.C.,Pinho F.J.,R.R. F.J. .2010 .Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis. Mem. Inst. Oswaldo Cruz, 105 : 92-98.
Martınez A.P.,Garcıa G.,Ridruejo E.,Perez M.J.,Neukam K.,Flichman D.,Lello F.A.D. .2019 .Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina. J. med, 91 : 1970-1978.
Miura M.,Maekawa S.,Sato M.,Komatsu N.,Tatsumi A.,Takano S.,Amemiya F.,Nakayama Y.,Inoue T.,Sakamoto M.,Enomoto N. .2014 .Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol. Res., 44 : E360-7.
Mushtaq S.,Hashmi A.H.,Khan A.,Kazmi S.M. A. .2022 .Emergence and persistence of resistance-associated substitutions in HCV GT3 patients failing direct-acting antivirals. Front, 13 : 894460.
Ohno O.,Mizokami M.,Wu R.R.,Saleh M.G.,Ohba K.,Orito E.,Mukaide M.,Williams R.,Lau J.Y. .1997 .New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a. J. clin. Microbiol, 35 : 201-207.
Patino-Galindo J.A.,Salvatierra K.,GonzalezCandelas K.,Lopez-Labrador F.X. .2016 .Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. , 60 : 15-2416.
Pawlotsky J.M. .2016 .Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology, 04 : 70-86.
Piselli P.,Serraino D.,Fusco M.,Girardi E.,Pirozzi A.,Tofolutti F.,Cimaglia C.,Taborelli M. .2021 .Hepatitis C virus infection and risk of liverrelated and non-liver-related deaths: A populationbased cohort study in Naples, southern Italy. BMC Infect. Dis., 21 : 667.
Rahimi P.,Sharafi H.,Bahramali G.,SajadianFard F.,Asadi N.S.,Alavian S.M.,Mobarakeh V.I.,Moravej S.Z. .2020 .Prevalence of naturallyoccurring NS5A and NS5B resistance-associated substitutions in iranian patients with chronic hepatitis C infection. , 11 : 617375.
Smith D.B.,Bukh J.,Kuiken C.,Muerhof A.S.,Rice C.M.,Stapleton J.T.,Simmonds P. .2014 .Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology, 59 : 318-327.
Soria M.E.,Garcia-Crespo C.,Martínez-González B.,Vázquez-Sirvent L.,Lobo-Vega R.,Ávila A.N.,Gallego I.,Chen Q.,García-Cehic D.,Llorens-Revull M.,Briones C.,Gómez J.,Ferrer-Orta C.,Verdaguer N.,Gregori J.,Rodríguez-Frías F.,Buti M.,Esteban J.I.,Domingo E.,Quer J.,Perales C. .2020 .Amino acid substitutions associated with treatment failure for hepatitis C virus infection. J. clin. Microbiol, 58 : 20-20.
Spengler U. .2017 .Direct antiviral agents (DAAs)-A new age in the treatment of hepatitis C virus infection. Pharmacol, 10 : 118-126.
Torge D.,Bernardi S.,Arcangeli M.,Bianchi S. .2022 .Histopathological features of SARS-CoV-2 in extrapulmonary organ infection: A systematic review of literature. Pathogens, 11 : 867.
Wyles D.L.,Luetkemeyer A.F. .2017 .Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens. Top. Antivir. Med, 25 : 103-109.
Younas S.,Sumrin A.,Hussain N.,Bilal M. .2022 .Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients. J. appl. Microbiol., 00 : 1-9.
Yousaf A.,Ghafoor A.,Fatima N.,Danish M. .2021 .Gender-specific frequency distribution of hepatitis C virus genotypes in Punjab province, Pakistan: A clinically significant descriptive crosssectional study. Cureus, 13 : .
Zeuzem F.,Mizokami M.,Pianko S.,Mangia K.H.,Martin R.,Svarovskaia E.,Dvory-Sobol H.,Doehle B.,Hedskog C.,Yun C.,Brainard D.M.,Knox S.,McHutchison J.G.,Miller M.D.,Mo H.,Chuang W.L.,Jacobson I.,Dore G.,Sulkowski M. .2017 .NS5A resistanceassociated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and efect on treatment outcome. J. Hepatol., 01 : 910-918.
Zia- ,Kow C.H.,Hasan S.S. .2021 .. on viral hepatitis services in Pakistan. Lancet Gastroenterol. Hepatol., 1253(21) : 00006-6.
0

Citations

0

Downloads

73

Views